Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has entered into an agreement ...

In January, Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for ...

Sometimes, they just put it off, said Dr. Antoine Pham, an internal medicine doctor with Thrive Medical. He has started prescribing a new kind of screening — the Shield blood test — for his patients ...

Guardant Health basically leads in liquid ... In fact, this aligns with the decline in COGS per "Reveal test" of over 50% projected for 2025. So, this is why I think that in the long run, GH's ...

PALO ALTO, Calif., March 25, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC ...

The Shield test will be reimbursed at the amount of $1,495 for Medicare patients during the initial nine-month ADLT period beginning April 1, 2025. During the initial ADLT period, Guardant Health ...

Guardant Health (GH) announced the Centers for Medicare & Medicaid Services CMS has approved Advanced Diagnostic Laboratory Test ADLT status for the Shield blood test for colorectal cancer CRC ...

Guardant Health shares were 11% higher, at $39.90, after the company said the Centers for Medicare & Medicaid Services has approved Advanced Diagnostic Laboratory Test status for the company's ...

Morningstar brands and products Company Portfolio ...

Guardant Health (GH) “announced its Shield blood test for colorectal cancer screening is now covered by a key healthcare insurance program for ...

Approval demonstrates unique value of Shield test for CRC screening and improves Medicare pricing PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology ...